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Abstract
Long Term Potentiation (LTP) is a leading candidate mechanism for learning and memory and is also thought to play a role
in the progression of seizures to intractable epilepsy. Maintenance of LTP requires RNA transcription, protein translation and
signaling through the mammalian Target of Rapamycin (mTOR) pathway. In peripheral tissue, the energy sensor AMP-
activated Protein Kinase (AMPK) negatively regulates the mTOR cascade upon glycolytic inhibition and cellular energy
stress. We recently demonstrated that the glycolytic inhibitor 2-deoxy-D-glucose (2DG) alters plasticity to retard
epileptogenesis in the kindling model of epilepsy. Reduced kindling progression was associated with increased recruitment
of the nuclear metabolic sensor CtBP to NRSF at the BDNF promoter. Given that energy metabolism controls mTOR through
AMPK in peripheral tissue and the role of mTOR in LTP in neurons, we asked whether energy metabolism and AMPK control
LTP. Using a combination of biochemical approaches and field-recordings in mouse hippocampal slices, we show that the
master regulator of energy homeostasis, AMPK couples energy metabolism to LTP expression. Administration of the
glycolytic inhibitor 2-deoxy-D-glucose (2DG) or the mitochondrial toxin and anti-Type II Diabetes drug, metformin, or AMP
mimetic AICAR results in activation of AMPK, repression of the mTOR pathway and prevents maintenance of Late-Phase LTP
(L-LTP). Inhibition of AMPK by either compound-C or the ATP mimetic ara-A rescues the suppression of L-LTP by energy
stress. We also show that enhanced LTP via AMPK inhibition requires mTOR signaling. These results directly link energy
metabolism to plasticity in the mammalian brain and demonstrate that AMPK is a modulator of LTP. Our work opens up the
possibility of using modulators of energy metabolism to control neuronal plasticity in diseases and conditions of aberrant
plasticity such as epilepsy.
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Introduction
Long Term Potentiation (LTP) is thought to represent one form
of durable alteration in synaptic strength underlying memory
formation[1]. Despite this potential role in learning and memory,
the ability to control aberrant LTP formation under pathological
conditions may be of therapeutic value. The initiating events in
LTP expression are rapid and require neither de-novo protein
synthesis nor transcription (termed Early LTP–E-LTP), however
LTP maintenance requires both protein translation and mRNA
transcription (Late LTP–L-LTP) [2,3,4,5]. This protein synthesis
appears to be dependent on mammalian Target of Rapamycin
(mTOR), a kinase complex that phosphorylates and activates key
positive regulators of protein translation including p70S6K kinase,
which then further phosphorylates the downstream target,
ribosomal protein S6 (rpS6) [6,7]. These downstream effectors
act to increase translation of select mRNAs that enhance overall
translational capacity [6,7,8].
In non-neuronal systems the mTORC1 complex of mTOR
can be controlled by cellular energy levels via the metabolic
sensor AMP-activated Protein Kinase (AMPK) [9]. A reduced
cellular ATP concentration results in elevation of AMP levels
[10] that, in concert with upstream kinases leads to full
activation of AMPK [11,12,13]. Activated AMPK coordinates
an energy-conserving program by increasing cellular ATP
production and reducing ATP consumption by shutting down
energy intensive processes such as mTOR-dependent protein
translation [9,14]. AMPK inhibits mTOR via phosphorylation
and activation of the Tuberous Sclerosis Complex (TSC) as well
as directly phosphorylating the RAPTOR subunit of mTORC1
[15] (Fig. 1A).
The anti-diabetic drug and mitochondrial complex-1 toxin
metformin is a potent activator of AMPK and both AMP
dependent and independent mechanisms such as Reactive
Nitrogen Species generation have been implicated in AMPK
activation by metformin [16,17,18]. The glucose analogue 2-
deoxy-D-glucose (2DG) is also able to activate AMPK through
glycolytic inhibition [19] and we recently showed that 2DG
administration suppresses epileptogenesis in the kindling model
[20].
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L-LTP expression, is controlled by neuronal metabolism. Given
that sustained LTP requires mTOR signaling, that mTOR is
under metabolic control via AMPK, and previous reports suggest
a link between energy metabolism and LTP [21,22,23], we
reasoned that energy metabolism could regulate L-LTP via
AMPK. Here we demonstrate that the energy sensor AMPK
controls hippocampal L-LTP and provide evidence that this
control is exerted through mTOR signaling.
Methods
All procedures were performed with the approval of the
University of Wisconsin-Madison School of Medicine and Public
Health Institutional Animal Care and Use Committee and
according to national guidelines and policies.
Electrophysiology
All electrophysiology was performed on 4–6 wk old C57BL/6
mice. Immediately after euthanasia the brain was removed from
the skull and submerged in ice cold cutting solution (CS) [in mM]:
110 sucrose, 60 NaCl, 3 KCl, 1.25 NaH2PO4, 28 NaHCO3, 0.5
CaCl2, 7 MgCl2, 5 glucose, 0.6 ascorbate). The hippocampi were
sectioned transversely in a Vibratome (St. Louis, MO) into
400 mM slices immersed in ice-cold CS. Slices were allowed to
recover for 45 min at room temperature (RT) in 50:50 CS:
artificial cerebrospinal fluid (ACSF) [in mM]: 125 NaCl, 2.5 KCl,
1.25 NaH2PO4, 25 NaHCO3, 2 CaCl, 1 MgCl2, 25 glucose), and
a further 45 min at RT in 100% ACSF before being transferred to
an interface chamber (Fine Science Tools, Foster City, CA) bathed
in 100% ACSF (1 mL/min) at 32uC (TC-324B, Warner
Instrument Corporation, Hamden, CT) for 2 hours prior to
treatment. All solutions were carb-oxygenated (95/5, O2/CO2).
Enameled bipolar platinum-tungsten (92:8 Pt:Y) stimulating
electrodes were placed along the Schaeffer-Collateral pathway.
Field EPSPs were recorded from CA1 stratum radiatum, with ACSF-
filled recording electrodes (5 MV). Baseline synaptic transmission
was assessed for each individual slice by applying gradually
increasing stimuli (0.5 V–15 V, 25 nA–1.5 mA, A-M Systems
model 2200 stimulus isolator, Carlsborg, WA) to determine the
input:output relationship. All subsequent experimental stimuli
were 50% of the intensity of the maximum evoked fEPSP slope
(i.e. PPF, HFS, TBS). Paired-pulse facilitation was performed prior
to the induction of LTP. PPF consisted of an initial single stimulus
to the Schaeffer Collateral bundle followed by a second stimulus of
equal magnitude. This paradigm was repeated with increasing
time intervals between the two pulses. fEPSP slope measurements
from the second pulse were plotted as a percentage of initial slope.
LTP was induced with either high frequency stimulation (4
stimulations of 100 Hz each lasting for 1 second) or theta burst
stimulation applied to the Schaeffer-collaterals and fEPSPs were
measured in stratum radiatum. Theta burst stimulation consisted of
10 bursts/train, and 3 trains/stimulus with a 20 second intertrain
interval. Each burst contained 4 stimulations at 100 Hz with an
interburst interval of 200 msec. Synaptic efficacy was continually
monitored (0.05 Hz). Every 2 min sweeps were averaged; the
Figure 1. Metformin and 2DG activate AMPK in hippocampal CA1 neurons. A) Schematic of the AMPK-mTOR pathway. B) AMPK is activated
30 min after exposure to 2DG (10 mM, p=0.019, n=9), metformin (5 mM, p=0.005, n=6), or phenformin (10 mM, p=0.018, n=6). Hippocampal slices
were incubated in ACSF and drug for 30 minutes and subjected to western blot with anti-phospho-Thr172-AMPK antibody followed by bIII-tubulin as
a loading control. Representative western blots of duplicate lanes are shown, together with their quantification from at least 10 samples per
condition (C). D) ATP levels are reduced in the presence of 10 mM 2DG. Slices were incubated in ACSF+10 mM 2DG (n=3) as above. Tissue was lysed
and subjected to a CellTiter-Glo ATP assay (Promega). E) 2DG activates AMPK in cell bodies of the pyramidal layer (PL) and dendrites of the stratum
radiatum (SR). Anti-phospho-Thr172-AMPK immunoreactivity is displayed in green. Neu-N is displayed in red. Scale bar: 10 mm.
doi:10.1371/journal.pone.0008996.g001
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(Digidata 1322B, Molecular Devices, Sunnyvale, CA) and then
analyzed (pClamp, Molecular Devices). Two-way ANOVA (drug
and time) with repeated measures (mixed model) and Bonferroni
posttests were used for statistical analysis for drug effect over all
points.
Tissue Homogenization for Biochemistry
Following drug application and/or stimulation, slices were flash
frozen in eppendorf tubes on dry ice. Slices were subsequently
lysed with RIPA buffer (50 mM Tris, 150 mM NaCl, 1% nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS) + mammalian
protease inhibitor (1:100, Sigma, St. Louis, MO) + phosphatase
inhibitors [in mM] (10 NaF, 2 Na Vanadate, 4 Na pyrophosphate,
10 b-glycerophosphate). Slices were then triturated with a 28.5
gauge insulin syringe to shear up DNA. Lysates were spun down at
12 krpm for 30 min and supernatants kept and quantified using
the DC Protein Assay (Bio-Rad, Hercules, CA). Appropriate
amounts of 5X loading buffer (0.5 M Tris, 10% SDS, 50%
glycerol, 10 mM EDTA,1% b-mercaptoethanol) were added to
protein extracts and boiled at 95uC for 3 min. All solutions were
diluted with Milli-Q water (Milli-Q UF Plus, Millipore, Bedford,
MA).
Western Blotting
Protein extracts were loaded at 30 mg/lane in gradient (4–20%)
tricine gels (Pierce Biochem, Rockford, IL) and resolved with
standard electrophoresis in HEPES buffer (100 mM Tris,
100 mM HEPES, 0.1% SDS) and transferred overnight at 4uC
onto PVDF membranes (Millipore, Bedford, MA) with tris-glycine
buffer (20 mM Tris, 1.5 M glycine). Membranes were blocked
with Tris-buffered salt solution with Tween-20 (TBST; 20 mM
Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20) and 5% milk fat for
1 hr prior to addition of primary antibody. To optimize binding,
primary antibodies were either diluted in 5% milk fat or TBST. p-
AMPK (Thr172) (1:1000 overnight at 4uC in TBST, Cell
Signaling, Danvers, MA), p-p70S6K (Thr389) (1:1000 overnight
at 4uC in TBST, Cell Signaling), p-rpS6 (Ser235/236) (1:1000
overnight at 4uC in TBST, Cell Signaling), total-p70S6K (1:1000
overnight at 4uC in TBST, Cell Signaling), total-rpS6 (1:1000
overnight at 4uC in TBST, Cell Signaling), bIII tubulin (1:10,000
for 1 hr at RT in milk, Promega, Madison, WI), actin (1:10,000 for
1 hr at RT in milk, Millipore). Membranes were incubated for
1 hr in horseradish peroxidase-conjugated goat anti-rabbit IgG or
goat anti-mouse IgG secondary antibodies (1:10,000) (Santa Cruz
Biotech All solutions were diluted with Milli-Q water (Milli-Q UF
Plus, Millipore, Bedford, MA). Protein bands were detected using
SuperSignal West Femto ECL reagent (Pierce Biochem) and
visualized using Kodak Image Station 2000R and Kodak 1D
Image Analysis software, which was also used to quantify protein
bands and the two-tailed Student’s T-test was employed for
statistical analysis.
Immunofluorescence and Microscopy
Tissue analysis was performed on 400 mm hippocampal slices
following incubation in either ACSF or ACSF plus 10 mM 2DG.
Slices were incubated overnight in a fixative solution containing
4% formaldehyde (freshly depolymerized from paraformaldehyde;
Sigma, St. Louis, MO) in 0.1 M phosphate buffer, pH 7.4 (PB).
Slices were removed from fixative, rinsed in PB and cryoprotected
in 50% PB/50% cryoprotectant with 20% sucrose and 5%
glycerol for 1 hour, followed by 100% cryprotectant with 20%
sucrose and 5% glycerol for 1 hour. Slices were frozen with dry ice
and sectioned on a sliding microtome in the coronal plane at
30 mm thickness. Sections were transferred to PB at 4uC (with
0.01% sodium azide if stored for more than 2 days).
Anti-phospho-AMPKa (Thr172) was purchased from Santa
Cruz (sc-33524, lot F0209). Anti-NeuN was purchased from
Millipore (MAB377, lot LV1573084). Sections from both septal
and temporal hippocampus were prepared for light microscopy.
Frozen sections were rinsed in 0.01 M phosphate buffered saline
(PBS) with 0.1% saponin (product S7900; Sigma Aldrich) and 2%
bovine serum albumin (BSA; Calbiochem, La Jolla, CA), blocked
in the same buffer with 20% normal goat serum for 45 minutes,
incubated overnight in primary antiserum to p-AMPKa (1:500)
and primary antiserum to NeuN (1:1000) with 0.1% normal goat
serum, washed in buffer, incubated for 2 hours in 1:500
AlexaFluor 488 goat anti-rabbit IgG (product A11034, lot
461250 from Molecular Probes, Eugene, OR) and 1:500
AlexaFluor 594 goat anti-mouse IgG (product A11032, lot
419361 from Molecular Probes, Eugene, OR) in PBS with 0.1%
saponin and 2% BSA, rinsed with PB and mounted with SlowFade
Light Antifade Kit (product S2828, lot 54616A from Molecular
Probes, Eugene, OR).
Three ‘‘positive’’ controls were performed to minimize the
possibility of artifactual staining. 1) p-AMPKa and NeuN were
visualized with both immunofluorescence and immunoperoxidase
reaction methods. 2) Dilution series were carried out to obtain
optimal staining dilutions. 3) p-AMPKa and NeuN antisera were
visualized on transcardial perfused tissue fixed with 4% formal-
dehyde. No discrepancies were observed in the pattern of label in
these comparisons. For a ‘‘negative’’ control, immunoreactions
were run without primary antisera. No label was observed with
this control.
Light microscopic imaging was performed with a digital camera
(Spot II; Diagnostic Instruments, Sterling Heights, MI) on a Nikon
E600 Eclipse epifluorescent microscope with x2–60 planapochro-
matic objectives and a standard FITC filter cube (FITC; EX 465–
495 nm; DM 505 nm; BA 515–555 nm) and TRITC filter cube
(TRITC; EX 528–553 nm; DM 565 nm; BA 600–660 nm).
Images were obtained with the x40 objective. Fluorescent images
were acquired at an initial 36-bit tone scale and saved as 16-bit
files. Light microscopic images were prepared for reproduction in
Adobe Photoshop 7.0 with minimal adjustments in the tone scale,
contrast, hue and subsequent sharpening with the unsharp mask
algorithm.
Results
AMPK Activation in the Hippocampus Represses mTOR
Signaling
To test the hypothesis that metabolism can control L-LTP via
the action of AMPK on mTOR signaling, we first tested whether
energy stress could activate AMPK in the hippocampus.
Hippocampal slices were incubated in either ACSF or ACSF
containing the glycolytic inhibitor 2-deoxy-D-glucose (2DG) for 30
minutes, and AMPK activation was assessed by measuring
phosphorylated AMPKa1/2 (p-AMPK). Exposure to 10 mM
2DG (a concentration that allows for competitive inhibition of
transporters and kinases of 25 mM glucose) resulted in a 2 to 3 fold
induction of p-AMPK compared to control slices (Fig. 1B and 1C).
This AMPK activation correlated with a 2 fold reduction in ATP
levels (Fig. 1D). The anti-diabetic drug metformin is a potent
activator of AMPK in other tissues: Figures 1B and 1C show that
5 mM metformin and the related molecule phenformin are also
able to activate AMPK 2 to 3 fold in the hippocampus. To
determine whether AMPK activation occurs in CA1 dendrites (the
site of mTOR activation upon LTP induction [6]) we visualized p-
AMPK and LTP
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Figure 1E shows that p-AMPK immunoreactivity is present both
in the dendrites of the stratum radiatum (SR) and cell bodies of the
pyramidal layer in CA1. Addition of 2DG results in a transition
from a punctate pattern to a smoother and brighter pattern in the
dendrites (compare panels 1 and 4). There is also a marked
increase in cell body staining in the presence of the AMPK
activator. The increased diffuse staining throughout the SR in the
presence of 2DG may be due to activation of AMPK in the glial
compartment. However, the observed activation of AMPK in the
dendrites demonstrates that hippocampal neurons contain the
necessary mechanisms to activate AMPK upon administration of
known AMPK inducers.
The mTOR pathway is activated in CA1 within 5 minutes of
High Frequency Stimulation (HFS) and is necessary for expression
of L-LTP [6,24]. Activation of mTOR can be monitored by
phosphorylation of its downstream targets and so we looked at the
mTOR substrate p70-S6Kinase (p70S6K) and its substrate
ribosomal protein S6 (rpS6) due to their established role directly
downstream of the mTOR kinase. We confirmed the observations
of Tsokas et al. that HFS of the Schaeffer Collaterals induces
phosphorylation of the mTOR cascade components p70S6K and
rpS6 [6] as judged by western blotting of protein from stimulated
or un-stimulated slices (Fig. 2). Consistent with the hypothesis that
AMPK activation suppresses mTOR signaling in the hippocam-
pus, high frequency stimulation failed to induce rpS6 or p70S6K
phosphorylation in the presence of 2DG.
AMPK Activation Prevents L-LTP Expression
Given the necessity of mTOR signaling for L-LTP expression,
we predicted that AMPK activation should prevent L-LTP
expression. To test this hypothesis, we initially tested the effects
of the AMPK activator 2DG on LTP that was induced using 2
different mTOR dependent paradigms: HFS and Theta Burst
Stimulation (TBS) [25]. HFS or TBS was delivered between CA1
and CA3 in the Schaeffer Collateral bundle in the presence or
absence of 2DG and field excitatory post-synaptic field potentials
(fEPSPs) were recorded in the stratum radiatum of CA1. Following
either HFS or TBS, the induction step of LTP was indistinguish-
able between 2DG treated and control slices (Fig. 3A and 3B,
respectively), consistent with this step being mTOR independent
[7]. However 60 minutes post-stimulation the 2DG-treated slices
failed to maintain L-LTP, which falls to 10% of untreated over the
course of 3 hours in the HFS paradigm and 30% in the TBS
paradigm.
We reasoned that if 2DG inhibits L-LTP via AMPK activation,
then other AMPK activators should also inhibit L-LTP. Therefore
we tested whether the AMPK activators metformin [16] or 5-
AminoImidazole-4-CarboxAmide Ribonucleoside (AICAR) [26]
could also inhibit L-LTP induced by TBS or HFS. Figure 3A and
3B show that similar to 2DG, 5 mM metformin suppressed L-LTP
but did not impact LTP induction. Figure 3B also shows that
AICAR inhibits L-LTP induced by TBS. Therefore, three
independent and structurally unrelated activators of AMPK
eliminated L-LTP that was elicited by two different stimulation
paradigms. Importantly, 2DG, AICAR and metformin did not
affect synaptic transmission per se because there was no significant
difference in the input/output relationship of the fEPSP slope
magnitude as a function of stimulus voltage when compared to
ACSF alone (Fig. 3C, top; AICAR vs. control, p=0.223; 2DG vs.
control, p=0.702; metformin vs. control, p=0.573).
If AMPK activation works to suppress mTOR signaling to
inhibit L-LTP, then the effects of AMPK activation would be
predicted to be postsynaptic given that LTP induction results in
dendritic rather than axonic mTOR activation [6]. To test this we
assessed whether 2DG, metformin or AICAR affected Paired-
Pulse Facilitation (PPF) (a protocol widely used to assess a
presynaptic component of a response to a stimulation or
compound [27]). The PPF protocol consists of an initial
stimulation followed by a second stimulation after a given interval.
The second stimulus evokes a greater response (measured as
fEPSP slope) than the initial stimulus due to residual Ca
2+ in the
presynaptic terminal which facilitates an increased amount of
neurotransmitter release. If a compound inhibits release, there will
be less neurotransmitter released initially, and therefore the second
stimulus will elicit a greater release of neurotransmitter and thus a
greater response. Figure 3C (bottom) shows that there was little
difference in PPF between control slices or those administered
drugs (AICAR vs. control, p=0.2061; 2DG vs. control,
p=0.6006; metformin vs. control, p=0.9076). This result is
consistent with the hypothesis that AMPK activation acts to inhibit
mTOR signaling to suppress L-LTP.
If AMPK activation is necessary for 2DG, metformin or
AICAR to inhibit L-LTP, then addition of an AMPK inhibitor
Figure 2. AMPK activation represses the mTOR pathway. 10 mM 2DG inhibits the hippocampal mTOR pathway. A) HFS was delivered to the
Schaeffer Collateral pathway of slices that had been incubated in the presence or absence of 10 mM 2DG for 30 minutes. Slices were then subjected
to western blot analysis using anti-phospho-Thr389-p70S6K, anti-p70S6K, anti-phospho-Ser235/236-rpS6 or anti-rps6 antibody. Representative
western blots of duplicate lanes and quantification (B) of 12 samples per condition are shown. Error bars show standard error of the mean (s.e.m).
*p,0.05.
doi:10.1371/journal.pone.0008996.g002
AMPK and LTP
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LTP. Figure 4 shows that in the presence of the potent AMPK
inhibitor compound-C [16], 2DG treatment failed to activate
AMPK (Fig. 4F). In the presence of compound-C, 2DG had no
effect on TBS-induced LTP expression (Fig. 4A). AMPK
inhibition using a structurally unrelated molecule, ara-A [28] also
prevented 2DG from repressing L-LTP expression (Fig. 4B). LTP
suppression by metformin was similarly inhibited by either
compound-C or ara-A (Fig. 4D and 4E respectively). Finally,
LTP suppression by the AMPK activator ACIAR was prevented
by compound-C (Fig. 4C). These data with three AMPK
activators and two inhibitors support the hypothesis that L-LTP
expression in the hippocampus is under metabolic control via the
metabolic sensor AMPK.
L-LTP inducing stimuli (e.g. TBS and HFS) rapidly activate
postsynaptic translational machinery in order to produce key
proteins involved in the induction and maintenance of LTP [5,29].
In the presence of protein synthesis inhibitors, LTP-inducing
stimuli produce short-term potentiation, yet fail to produce lasting
LTP [30,31]. However, LTP is unaffected if protein synthesis
inhibitors are added just after the tetanus [24]. Late-Phase LTP
elicited by either HFS or TBS is eliminated by the mTOR
inhibitor rapamycin. Further, Cammalleri et al. demonstrated a
critical time window of rapamycin sensitivity in inhibition of L-
LTP: exposure to rapamycin during tetanic stimulation is sufficient
to prevent expression of LTP two hours later [24]. If AMPK
activation represses mTOR signaling to inhibit L-LTP, then
metformin exposure solely during the stimulation protocol should
be sufficient to prevent L-LTP expression. Figure 5B shows that
metformin administration during TBS followed by wash-out
immediately after the stimulation paradigm generates a loss of
L-LTP identical to that seen in the continued presence of
metformin (Fig. 3B). To show that this was not due to persistence
of metformin after wash out, metformin was added and washed
out prior to stimulation, with no effect on L-LTP (Fig. 5A). Also,
addition of metformin after stimulation for the remaining three
hours had no significant effect on L-LTP (Fig. 5C). This result
suggests that a critical period of metformin/AMPK sensitivity
exists during the induction phase of LTP, which overlaps with the
mTOR dependent period defined by Cammalleri et al.
To explore the role of mTOR in AMPK modulation of LTP we
took advantage of the observation that treating slices with the
AMPK inhibitors compound-C or ara-A results in hyper-
potentiation (Fig. 6A). If AMPK inhibition results in heightened
LTP due to de-repression of mTOR signaling then in the presence
of the mTOR inhibitor rapamycin, compound-C should have no
effect. Figure 6B shows that as reported by others, rapamycin
eliminates L-LTP induced by TBS. Compound-C fails to elevate
LTP in the presence of rapamycin suggesting that AMPK
modulation of LTP requires mTOR signaling. In aggregate, these
physiological measurements, together with the molecular analyses
suggest a model whereby AMPK activation inhibits maintenance
of LTP at least in part, through suppression of the mTOR
pathway.
Discussion
The work presented here suggests that LTP is under metabolic
control via the energy sensor AMPK. This is supported by the
observation that three structurally distinct activators of AMPK
(2DG, metformin and AICAR) suppress L-LTP expression in two
different LTP paradigms (HFS and TBS) (Fig. 3). Secondly, LTP
suppression by 2DG, metformin and AICAR can be overcome by
two inhibitors of AMPK that are structurally and mechanistically
Figure 3. AMPK activation inhibits L-LTP expression. A) AMPK activation inhibits LTP induced by HFS. 10 mM 2DG (n=10) reduces L-LTP to
10% of control (n=20) (p=0.034). 5 mM metformin (n=8) reduces L-LTP to 40% of control (p=0.028). B) AMPK activation inhibits LTP induced by TBS.
10 mM 2DG reduces L-LTP (p=0.022, n=7) to 30% of control (n=13), 5 mM metformin reduces L-LTP (p=0.042, n=12) to 51% of control. 1 mM
AICAR reduces L-LTP (p=0.0025, n=8) to 11% of control C) 2DG, metformin and AICAR do not have an effect on basic synaptic transmission. Top:
input-output relationships for Schaeffer collateral stimulation and fEPSP slope measured in the presence of ACSF (n=27), 10 mM 2DG (n=14), 5 mM
metformin (n=17) or 1 mM AICAR (n=8). Bottom: Paired Pulse Facilitation is not affected by the presence of 10 mM 2DG (n=11), 5 mM metformin
(n=17) or 1 mM AICAR (n=8) compared to ACSF alone (n=14). Results are plotted as the ratio of fEPSP slopes (2
nd stimulus/1
st stimulus X100) as a
function of interpulse interval (0–300 msec). *p=0.0002. A and B) Inset: representative fEPSP traces shown were taken 4 minutes prior and 180
minutes after stimulation. Error bars show s.e.m.
doi:10.1371/journal.pone.0008996.g003
AMPK and LTP
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suppressive effects of AMPK activation work at least in part
through the mTOR pathway. This hypothesis is supported by the
observation that the AMPK activator 2DG suppresses phosphor-
ylation and activation of the downstream mTOR pathway
components, p70S6K and rpS6 upon High Frequency Stimulation
Figure 5. AMPK activation suppresses L-LTP within a time-restricted window. A) 5 mM metformin was added 20 minutes prior to TBS and
washed out immediately prior to TBS (n=8). L-LTP at 180 minutes post TBS was equal to control (n=17), B) metformin was added immediately prior
to TBS and washed out immediately after TBS (n=8). L-LTP was reduced to 30% of control (p=0.0172). C) metformin was added 5 min after
stimulation for the duration of the experiment (n=5). L-LTP at 180 minutes was indistinguishable from control. Control data in Fig. 5A is reproduced
in Fig. 5B and Fig. 5C for comparison. Inset: Representative fEPSP traces shown were taken 4 minutes prior to and 180 minutes after TBS. Error bars
show s.e.m.
doi:10.1371/journal.pone.0008996.g005
Figure 4. AMPK inhibition rescues L-LTP expression. AMPK inhibitors prevent TBS-induced L-LTP loss in the presence of 2DG, metformin or
AICAR. A) 1 mM compound-C (n=9) or B) 100 mM araA (n=6) prevent 10 mM 2DG-mediated loss of L-LTP. C) 1 mM compound-C prevents 1 mM
AICAR-mediated loss of L-LTP (n=6). D) 1 mM compound-C (n=9) or E) 100 mM araA (n=6) prevents 5 mM metformin-mediated loss of L-LTP. Control
data from Fig. 3B is reproduced in Fig. 4A and Fig. 4B for comparison. A–E) Inset: representative fEPSP traces shown were taken 4 minutes prior and
180 minutes after stimulation. F) 1 mM compound-C abolishes 10 mM 2DG-mediated AMPK activation. Slices were incubated in ACSF (n=8), 10 mM
2DG (n=5) or both 10 mM 2DG and 1 mM compound-C (n=6) for 30 minutes, subjected to western blotting and quantified as in Fig. 1A. *p=0.0002.
Error bars show s.e.m.
doi:10.1371/journal.pone.0008996.g004
AMPK and LTP
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by the AMPK inhibitor compound-C suggesting that AMPK is
upstream of mTOR in regulating LTP (Fig. 6). Thirdly, AMPK
activators fail to alter Paired Pulse Facilitation, which suggests a
post-synaptic mode of action, consistent with the site of mTOR
activity [7,32]. Fourthly, AMPK activation restricted to the
stimulation period is sufficient to prevent L-LTP expression three
hours later, an observation consistent with the time period
required for mTOR activity to maintain L-LTP [24]. Data
presented here connects AMPK to neuronal mTOR signaling
thereby linking energy and metabolic status to LTP. In
conjunction with published work describing the role of mTOR
in LTD [33], our work suggests that neuronal plasticity in general
is under the direct control of cellular energy metabolism through
AMPK.
Late-Phase LTP requires MAPK/ERK and PI3/AKT signal-
ing that activates the mTOR pathway and dendritic protein
translation [6]. L-LTP also has a requirement for gene
transcription including a critical role for the cAMP Response
Element Binding protein (CREB) activity and BDNF expression
[5,34,35]. Interestingly CREB and TORC1 signaling is known to
be modulated by AMPK in peripheral tissue [13,36,37],
suggesting that AMPK may also work through CREB to control
plasticity.
In addition to positively regulating protein synthesis, mTORC1
contributes to a variety of other cellular processes, some of which
have been linked to neuronal function. mTOR activity impacts
mitochondrial function by increasing oxidative capacity and
promoting the transcription of key components of the electron
transport chain [38,39]. Consequently, hyperactive mTOR
signaling increases the generation of reactive oxygen species
(ROS), which are required for LTP [40]. Hence it is possible that
inhibition of mTOR signaling by AMPK activation could suppress
LTP via a reduction in ROS production.
Additionally, mTOR acts to inhibit glycogen synthase kinase 3b
(GSK3b) signaling [41]. Given the potential role of GSK3b in
enhancing LTP [42], activation of GSK3b via mTOR inhibition
may also contribute to loss of LTP in our system. Nevertheless, our
results suggest that the negative regulation of mTOR signaling by
AMPK links energy sensing to plasticity.
Several reports have demonstrated an increased fEPSP when
glucose is replaced by 2DG for some time period [43,44,45]. In
these studies, 2DG application results in a decreased fEPSP slope,
which is reversed upon switching back to normal ACSF leading to
potentiation. Zhao et al. reported that 2DG suppresses synaptic
transmission through release of adenosine and activation of pre-
synaptic adenosine receptors [46]. This would imply a pre-
synaptic mode of action for 2DG and would result in an altered
PPF (compared to control) at CA1. In our hands we do not see an
effect on PPF by 2DG or metformin, which is consistent with the
hypothesis that the effects of AMPK are primarily post-synaptic. It
is therefore unlikely that the negative regulation of LTP by AMPK
works through adenosine release. The discrepancy between the
results reported by Zhao et al. and our work is most likely due to
the fact that Zhao et al. replace glucose with 2DG in their ACSF.
We administer 10 mM 2DG in the presence of 25 mM glucose in
ACSF and this results in a tempering of ATP production to 50% of
ACSF alone (Fig. 1D), yet does not alter baseline synaptic
responses out to four hours of recording (data not shown). This
major difference in paradigm most likely explains why Zhao et al.
observe a pre-synaptic effect by 2DG via adenosine release
whereas our 2DG effects are post-synaptic, as judged by the lack of
change in PPF.
Our findings that AMPK controls LTP may provide a cellular
and molecular basis for the observations that increased glucose
availability enhances learning and memory [47,48,49,50].
During exploratory behavior, plasma brain glucose levels drop.
When glucose levels are maintained with glucose injections, rats
Figure 6. AMPK regulation of L-LTP is rapamycin sensitive. A) 1 mM compound-C (n=8, p=0.0069) or 100 mM ara-A (n=8, p=0.0045) results
in heightened potentiation after TBS compared to ACSF alone (n=14). B) 1 mM rapamycin results in suppression of L-LTP to 33% of control (n=4,
p=0.0097). 1 mM compound-C in the presence of rapamycin fails to significantly enhance L-LTP above rapamycin alone (n=9, p=0.2706). Control
data in Fig. 6A is reproduced in Fig. 6B for comparison. Inset: Representative fEPSP traces shown were taken 4 minutes prior to and 180 minutes after
TBS. Error bars show s.e.m.
doi:10.1371/journal.pone.0008996.g006
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Rats injected with glucose immediately after training in this
same avoidance test showed enhanced retention of memory
24 hours later compared to controls. However, injection 1 hour
after training had no effect on retention [47]. Similarly, intra-
amygdala glucose injection helped the extinction of conditional
place preference only when glucose administration occurred
immediately after training but not two hours later [51]. The
ability of glucose to impact learning and memory tasks implies
that learning and memory mechanisms are under metabolic
control.
The inability of glucose to improve behavioral outcomes when
administered 1–2 hours after training as compared to directly
after is consistent with our findings that AMPK activation must
occur during the stimulation period to inhibit L-LTP. mTOR
activity is not continuously required after LTP induction in
order to sustain L-LTP but instead is necessary only during the
stimulus period [24]. This suggests that de novo protein synthesis
upon induction generates products required to maintain LTP in
the absence of continued stimulation. In keeping with this
model, our data shows that a narrow time window exists during
which AMPK activation is sufficient to suppress L-LTP: the
presence of metformin just during the stimulus period followed
by wash-out prevents LTP maintenance whereas addition of
metformin immediately after stimulation for the duration of the
experiment has no effect on L-LTP (Fig. 5). This result suggests
that acute suppression of mTOR via AMPK activation during
the short induction phase of LTP prevents expression of chronic
L-LTP.
It is tempting to consider that AMPK modulation of L-LTP in
vitro reflects AMPK modulation of learning and memory in vivo.
Indeed Dash et al. demonstrated that activation of neuronal
AMPK with hippocampal injections of AICAR reduced long-term
memory and this was associated with reduced phosphorylation of
mTOR cascade components. Importantly, glucose injection
directly into the rat hippocampus improved long-term spatial
memory in the Morris Water Maze and this was associated with
decreased AMPK phosphorylation/activation and increased
activity of the mTOR cascade [52]. The fact that AMPK activity
can be reduced in the hippocampus and result in heightened long-
term memory demonstrates that under physiological conditions,
latent AMPK activity tempers long-term memory mechanisms.
This notion is consistent with the observation that application of
AMPK inhibitors (compound-C and ara-A) in the absence of
AMPK agonists result in heightened LTP (Fig. 6). Therefore we
argue that metabolic regulation of LTP and long-term memory is
not only important under pathological conditions where energy
stress may be present but is also important under physiological
conditions. The results presented here along with published work
supports a model whereby neuronal energy status controls LTP
maintenance through the action of AMPK on mTOR dependent
dendritic protein translation.
The possibility of controlling plasticity through AMPK may
offer a route to therapeutic intervention in certain neurological
disorders. Tuberous Sclerosis is caused by mutations in the TSC1
or TSC2 gene and is often associated with autism, mental
retardation and epilepsy [53,54]. Loss of TSC function results in
heightened mTOR activity and inappropriate LTP induction
upon a single high frequency stimulation in slice experiments [55].
Importantly, addition of the mTOR inhibitor rapamycin reverses
many of the behavioral deficits in TSC mutant mice and prevents
inadvertent maintenance of LTP. These intriguing results indicate
that pharmacological suppression of heightened mTOR signaling
in Tuberous Sclerosis patients might be of therapeutic value. Our
work suggests that the widely used anti-type II diabetes drug
metformin can suppress mTOR signaling through activation of
AMPK in the hippocampus. Metformin is used by around 35
million people in the U.S alone, is able to cross the blood-brain
barrier and has few contra-indications when prescribed appropri-
ately [16,56,57]. The absence of a functional TSC1/2 complex
prevents AMPK from inhibiting mTOR signaling through
phosphorylation of TSC2, however work by Gwinn et al. shows
that AMPK can also suppress mTOR through the targeting of
RAPTOR [15]. Therefore, heightened mTOR signaling in TSC
patients could feasibly be attenuated therapeutically through the
action of metformin on AMPK and RAPTOR.
We show that the glycolytic inhibitor 2DG is a potent activator
of AMPK, prevents stimulation-induced mTOR activation, and
suppresses L-LTP in an AMPK-dependent manner. These
properties are of particular interest because we recently showed
that 2DG retards epileptogenesis in the rat electrical kindling
model of temporal lobe epilepsy [20]. This modulation of activity
dependent plasticity was associated with reduced BDNF and TrkB
expression and increased recruitment of the metabolic sensor
CtBP to the transcriptional repressor NRSF/REST [58,59].
BDNF is an upstream component of the mTOR cascade and is
sufficient to enhance potentiation at CA1 synapses in a rapamycin
sensitive manner [7]. Therefore mTOR dependent LTP may be
regulated by metabolism via a transcription dependent mechanism
through CtBP and via a post-translational mechanism through
AMPK. It will be interesting to test whether metformin, working
through AMPK has the same effects as 2DG working through
CtBP in retarding kindling and epileptogenesis. In summary, we
show that plasticity is under metabolic control through the activity
of the master energy regulator, AMPK.
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